Programmed Death – Ligand 1 Expression in Malignancy of Thyroid Follicular Epithelial Cell Origin
Keywords:
PD-L1, thyroid cancer, papillary thyroid carcinoma, follicular thyroid carcinoma, poorly differentiated thyroid carcinoma, anaplastic thyroid carcinomaAbstract
Several previous studies reported the fact that expression of Programmed Death – Ligan 1 (PD-L1) in various types of histopathology of thyroid cancer showed varied results and had predictive value and prognosis that were expected to be targeted for anti PD-1/PD-L1 immunotherapy. The aim of this study was to evaluate comparison expression of PD-L1 one to each other group between papillary thyroid carcinoma (PTC), follicular thyroid carcinoma (FTC), poorly differentiated carcinoma (PDTC) and anaplastic thyroid carcinoma (ATC). This study was an observational analytic with a cross sectional design using paraffin block samples from three anatomic pathology laboratories in Makassar during the periode of July 2015 – February 2019. PD-L1 expression was evaluated using Rabbit Monoclonal Antibody (28-8) and data were analysed using The Mann – Whitney Test. There was a significant difference of PD-L1 expression score between PTC with PDTC (p = 0,045 ; p < 0,05) and ATC (p = 0,046 ; p < 0,05), whereas there was no significant difference of PD-L1 expression score between PTC with FTC (p = 0,371 ; p > 0,05), between FTC with PDTC (p = 0,147 ; p > 0,05) and ATC (p = 0,069 ; p > 0,05), also between PDTC with ATC (p = 0,483 ; p > 0,05). But overall, PD-L1 expression showed higher expression in a subset of advanced thyroid cancers such as poorly differentiated thyroid carcinoma and anaplastic thyroid carcinoma.
References
Briseis AK, Tongzhang Z, Theodore RH, Xuesong H, Mary HW, Andreas S, Yagun Z, Yana B, Cairong Z, Grace LG, Nathaniel R, and Yawei Z. “International pattern and trends in thyroid cancer incidence 1973-2002”. NIH Public Access, Cancer Causes Control, 20(5), 525-31, July 2009, doi: 10.1007/s10552-008-9.
Hiroshi Katoh, Keichi Yamashita, Takumo Enomoto, Masahiko Watanabe. “Classification and General Considerations of Thyroid Cancer”. Annals of Clinical Pathology, 1-9, March 2015.
Alan P. Farwell. “Thyroid cancer, The increased incidence of thyroid cancer is worldwide”. A publication of the American Thyroid Association, Vol.10, 9, February 2017.
Edge, S. B., & Compton, C. C. “The american joint committee on cancer: The 8th edition of the AJCC cancer staging manual and the future of TNM”. Annals of Surgical Oncology, 17(6), 1471–74, 2018.
Data and Information Center of the Health Ministy of the Republic of Indonesia, 1-8, 2015.
Massimo Santoro and Francesca Carlomagno. Pathogenesis of Thyroid Carcinoma. Thyroid Diseases, pathogenesis, diagnosis, and treatment, Springer, 546-58, 2018.
LiVolsi, Virginia A. “Papillary Thyroid Carcinoma : An Update.” Modern Pathology, 24 (S2). Nature Publishing Group : S1-9, 2011, doi : 10.1038/modpathol.2010.129.
Hsiao, Susan J and Yuri E. Nikiforov. “Molecular Approaches to Thyroid Cancer Diagnosis”. Endocrine-Related Cancer 21 (5) : 301-13, 2014, DOI : 10.1530/ERC-14-0166.
King-yin Lam, Alfred. “Pathology of Endocrine Tumors Update : World Health Organization New Classification-Other Thyroid Tumors” 22 (4) : 209-16, 2017, doi : 10.1097/PCR.0000000000000183.
Angell TE, Lechner MG, Jang JK, Correa AJ, LoPresti JS & Epstein AL 2014 BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration. Thyroid 24 1385–1393. (doi:10.1089/ thy.2014.0134)
Arlene H S., et al. The function of programmed cell death 1 and its ligand in regulating autoimmunity and infection. Nature Immunology, 8: 239-245, 2007.
Bastman JJ, Serracino HS, Zhu Y, Koenig MR, Mateescu V, Sams SB, Davies KD, Raeburn CD, McIntyre RC, Haugen BR Jr, et al. “Tumor-infiltrating T Cells and the PD-1 checkpoint pathway in advanced differentiated and anaplastic thyroid cancer”. Journal of Clinical Endocrinology & Metabolism 101, 2863–73, 2016, doi:10.1210/ jc.2015-4227.
Chen J., Jiang,C.C., Jin L., and Zhang, Z. D. Regulation of PDL1 : A novel role of prosurvival signalling in cancer, 1–31, 2015.
Chowdhury S, Veyhl J, Jessa F, Polyakova O, Alenzi A, MacMillan C, Ralhan R & Walfish PG. “Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants”. Oncotarget 7, 32318–28, 2016, doi:10.18632/ oncotarget.8698.
Dong, Y., Sun, Q., & Zhang, X. PD-1 and its ligands are important immune checkpoints in cancer, 8(2), 2171-86, 2017.
Hashem O A., et al. “PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy : Mechanism, Combination, and Clinical Outcome”. Frontiers in Pharmacology, 8 : 1-15, 2017.
Jake S O, Georgina V L, et al. Resistance to PD1/PDL1 checkpoint inhibition. Cancer Treatment Review, Elsevier,52 : 71-81, 2016, http://dx.doi.org/10.1016/j.ctrv.2016.11.007.
Paul J Davis. “PD-L1 and PD-1 gene expression are both stimulated by thyroid hormone in cancer cells”. Cell & Stem Cell Research. 8 : 1, 2017, http://dx.doi.org/10.4172/2157-7013.C1.028.
Rosenbaum M W, Gigliotti B J. “PD-L1 and IDO1 are Expressed in Poorly-Differentiated Thyroid carcinoma”. Endocrin Pathology, March 2018, PMCID : PMC6500591.
Salvatore U, Chiara T, and Enke B. “PD-1 Ligand Expression in Epithelial Thyroid Cancers : Potential Clinic Implications”. International Journal of Molecular Sciences, March 2019, doi: 10.3390/ijms20061405.
Ahn S, Kim T H, Kim S W, Ki C S, Jang H W, Kim J S, Kim J H, Shin J H, Hahn S Y, Oh Y L, and Chung J H. Comprehensive screening for PD-L1 expression in thyroid cancer. Endocrine-Related Cancer. Bioscientifica, 24, 97-106, 2017 http://dx.do.org/10.1530/ERC-16-0421.
Cunha LL, Marcello MA, Morari EC, Nonogaki S, Conte FF, Gerhard R, Soares FA, Vassallo J & Ward LS. “Differentiated thyroid carcinomas may elude the immune system by B7H1 upregulation”. Endocrine- Related Cancer 20 103–10, 2013, doi:10.1530/ERC-12-0313.
Chintakuntlawar A V., et al.” Expression of PD-1 and PD-L1 in anaplastic thyroid cancer patients treated with multimodal therapy: results from a retrospective study”. The Journal of Clinical Endocrinology & metabolism, 1-14, 2017, DOI : 10.1210/jc.2016-3756.
Lim SM, Shin SJ, Chung WY, Park CS, Nam KH, Kang SW, Keum KC, Kim JH, Cho JY, Hong YK, et al. 2012 Treatment outcome of patients with anaplastic thyroid cancer: a single center experience. Yonsei Medical Journal 53 352–357. (doi:10.3349/ymj.2012.53.2.352).
Laura Sterian Ward. “Review Article : Immune Respone in Thyroid Cancer : Widening the Bounderies". Hindawi Publishing Corporation Scientifica, 1-20, Sept 2014, http://dx.doi.org/10.1155/2014/125450.
Wu H, Sun Y, Ye H, Yang S, Lee SL & de las Morenas A. “Anaplastic thyroid cancer: outcome and the mutation/expression profiles of potential targets”. Pathology & Oncology Research 21, 695–701, 2015, doi:10.1007/s12253-014-9876-5.
Bryant Furlow. PD-L1 a Potential Target In Thyroid Cancer?. ATA Thyroid Cancer, 32-9, 2015.
Francisco L M., et al . “The PD-1 pathway in tolerance and autoimmunity”. Immunological Review, 236 : 219- 42, 2010.
Downloads
Published
How to Cite
Issue
Section
License
Authors who submit papers with this journal agree to the following terms.
